Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 172 от 222

Набира участници

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

Arrhythmias, Cardiac Breast Cancer Prostatic Cancer Brain Cancer +5

This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance. Routinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. When the markerless tracking method is sufficiently advanced, according to the PI of each of the data collection sites, the markerless tracking method will be run in parallel to, but not intervening with, patient treatments during data acquisition.

Начало: 28.02.2023 Край: 31.01.2026 Възраст: от 18 г.

Australia University of Sydney NCT05184790

Набира участници Фаза 3

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Areata Alopecia Alopecia Hypotrichosis Hair Diseases +2

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.

Начало: 27.02.2023 Край: 01.02.2030 Възраст: 6–17 г. Лечение

Argentina, Australia, Canada +9 Eli Lilly and Company NCT05723198

Набира участници Фаза 1/2

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.

Начало: 27.02.2023 Край: 12.05.2027 Възраст: 18–65 г. Лечение

Australia, Belgium, Canada +7 Vertex Pharmaceuticals Incorporated NCT05668741

Набира участници Фаза 3

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Low-grade Glioma Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma Pediatric Low-grade Glioma

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.

Начало: 27.02.2023 Край: 01.06.2031 Възраст: до 25 г. Лечение

Australia, Belgium, Brazil +24 Day One Biopharmaceuticals, Inc. NCT05566795

Набира участници

Use of Artificial Intelligence-Guided Echocardiography to assIst cardiovascuLar Patient managEment

Heart Failure Valve Heart Disease

Heart Failure and valvular heart disease are disproportionate problems in rural and remote Australia (RRA). Echocardiography is the best imaging investigation, and essential for management, but access to this essential test shows huge geographic variations, primarily because of dependence on expert acquisition. This trial seeks to demonstrate the effectiveness of artificial intelligence-based echocardiography for triage and management of patients with known or suspected heart disease in RRA.

Начало: 24.02.2023 Край: 30.06.2026 Възраст: от 45 г. Диагностика

Australia Baker Heart and Diabetes Institute NCT05558605

Набира участници Фаза 1

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Acute Myeloid Leukemia

This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Preliminary estimates of efficacy will be obtain through a dose expansion cohort receiving the maximum tolerated dose from the dose escalation phase of the study. This study aims to determine the safety of talazoparib in combination with conventional chemotherapy and to establish the maximum tolerated dose of all 3 drugs when given in combination. A preliminary estimate of efficacy through a dose expansion phase is a secondary aim.

Начало: 23.02.2023 Край: 01.04.2027 Възраст: до 21 г.

United States Norman J. Lacayo NCT05101551

Набира участници Фаза 2

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Immunodeficiency Hematopoietic Stem Cell Transplantation

Background: Allogeneic hematopoietic stem cell transplant involves taking blood stem cells from a donor and giving them to a recipient. The transplants are used to treat certain diseases and cancers. Researchers want to see if the transplant can treat VEXAS Syndrome. Objective: To see if stem cell transplants can be successfully performed in people with VEXAS and even improve the disease. Eligibility: People ages 18-75 who have VEXAS Syndrome that has caused significant health problems and standard treatment either has not worked or is not available. Design: Participants will be screened with: Physical exam Medical review Blood and urine tests Heart and lung function tests Bone marrow biopsy Participants will have a chest x-ray. They will have an imaging scan of the head, chest, abdomen, pelvis, and sinus. They will have a bone density scan. They will have a dental exam and eye exam. They will meet with specialists. They will repeat some screening tests. Participants will be admitted to the NIH hospital. They have a central venous catheter put into a vein in the chest or neck. They will receive drugs to prepare their bone marrow for the transplant. They may have total body irradiation. They will receive the donor stem cells through the catheter. They will get other drugs to prevent complications and infections. After discharge, they must stay in the DC area for 3 months for weekly study visits. Participants will have study visits 30, 60, 100, 180, 210, 240, 300, and 360 days later. After that, they will have yearly visits for 2 years and then be contacted yearly by phone....

Начало: 23.02.2023 Край: 01.07.2026 Възраст: 18–75 г.

United States National Cancer Institute (NCI) NCT05027945

Набира участници

Stereotactic Liver Ablation Assisted With Intra-Arterial CT Hepatic Arteriography and Ablation Confirmation Software Assessment (STEREOLAB)

Liver Ablation Hepatic

To achieve adequate tumor treatment coverage with sufficient minimal ablation margins, several steps are required: firstly, it is critical to define tumor boundaries and extent on intra-procedural CT image; secondly, accurate planning, targeting, and confirmation of ablation probe placement within the tumor; thirdly, the use of an intra-procedural imaging assessment method to evaluate minimal ablation margins is required to define whether sufficient minimal ablation margins was obtained or if additional ablation is needed. Taking all together, those factors points to the need of having a high-precision ablation methodology for intra-procedural planning, monitoring, and ablation margin assessment. Currently, such methods are only utilized in isolation and the benefit of a combined and standardized procedure workflow is unknown. Therefore, our primary goal of this single-arm clinical trial is to investigate the technical efficacy of a high-precision liver ablation technique comprised by stereotactic-guidance, CT during hepatic arteriography-based imaging analysis, and computer-based software assessment of ablation margins for the treatment of patients referred to ablation for the treatment of primary and secondary liver cancers.

Начало: 21.02.2023 Край: 31.08.2026 Възраст: от 18 г.

United States M.D. Anderson Cancer Center NCT05361551

Набира участници Фаза 2

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Cancer Harboring BRAF Alterations HGG LGG Solid Tumors

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.

Начало: 21.02.2023 Край: 28.12.2026 Възраст: от 10 г. Лечение

Australia, Canada, France +8 Fore Biotherapeutics NCT05503797

Набира участници Фаза 1

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Colorectal Cancer Gastric Cancer Ovarian Cancer

This is a Phase 1 open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 as monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced micro satellite-stable (MSS) colorectal cancer, or gastric or ovarian cancer. The study is run in 2 parts. Phase 1a is dose escalation IVX037 monotherapy and Phase 1b is IVX037 with checkpoint inhibitor, sintilimab.

Начало: 17.02.2023 Край: 30.11.2028 Възраст: 18–85 г. Лечение

Australia ImmVirx Pty Ltd NCT05427487

Набира участници

PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation

Atrial Fibrillation

Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood. The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3 years following ablation using clinical variables and innovative biomarkers in a prospective cohort of 750 patients undergoing atrial fibrillation catheter ablation. The secondary aims are to assess the incidence of major adverse cardiovascular outcomes (MACE) and the incidence of major bleeding within the 3 years Wolfing catheter ablation.

Начало: 16.02.2023 Край: 01.02.2031 Възраст: от 18 г.

France University Hospital, Lille NCT05009797

Набира участници Фаза 4

A Randomised Controlled Trial of N-acetylcysteine for the Management of Alcohol Use Disorder

Alcohol Use Disorder (AUD)

To explore the effectiveness of n-acetylcysteine in improving treatment outcomes for alcohol use disorder in a double-blind randomised placebo-controlled trial.

Начало: 16.02.2023 Край: 01.11.2026 Възраст: 18–70 г. Лечение

Australia University of Sydney NCT05408247

Набира участници

High-Risk prostatE Cancer radiatiOn Versus surgERy

Prostate Cancer Prostate Adenocarcinoma

Prospective cohort study comparing robot-assisted radical prostatectomy and external beam radiotherapy +/- androgen deprivation therapy for high-risk non-metastatic prostate cancer in terms of health-related quality of life, functional outcomes, cost-effectiveness, progression-free survival and distant metastasis-free survival.

Начало: 16.02.2023 Край: 30.06.2030 Възраст: 50–75 г.

Netherlands Comprehensive Cancer Centre The Netherlands NCT05931419

Набира участници Фаза 1

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

HR+/HER2-negative Breast Cancer

The goal of this clinical trial is to evaluate the safety and efficacy of TOS-358 in women with HR+ HER2- metastatic breast cancer whose tumors have a mutation in PIK3CA and who meet all other study enrollment criteria. The main questions it aims to answer are: 1. Phase 1a: what is the maximum tolerated dose and recommended dose for phase 2? 2. Phase 1a: how safe and tolerable is TOS-358 at different dose levels when taken orally once or twice per day? 3. Phase 1b: how safe and effective is TOS-358 when given with standard of care medicines for HR+HER2- metastatic breast cancer (fulvestrant and CDK4/6i)

Начало: 15.02.2023 Край: 01.12.2027 Възраст: от 18 г.

Spain, United States Totus Medicines NCT05683418

Набира участници Фаза 3

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Ischemic Stroke; Ischemic Attack, Transient

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Начало: 15.02.2023 Край: 09.12.2026 Възраст: от 40 г. Лечение

Argentina, Australia, Belgium +40 Janssen Research & Development, LLC NCT05702034

Набира участници Фаза 2

A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)

The main goal of this phase llb study is to compare the efficacy and safety of two doses of HEC585 tablets with placebo which is a look-alike substance that contains no active drug in patients with progressive fibrosing interstitial lung diseases. This study is divided into two stages, i.e. main study stage with 24 weeks treatment duration followed by up to 96 weeks treatment extended study stage.

Начало: 15.02.2023 Край: 01.12.2026 Възраст: от 18 г.

China Sunshine Lake Pharma Co., Ltd. NCT05139719

Набира участници Фаза 3

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Primary Generalized Tonic-Clonic Seizures

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).

Начало: 14.02.2023 Край: 01.06.2027 Възраст: от 12 г. Лечение

Argentina, Australia, Belgium +15 Xenon Pharmaceuticals Inc. NCT05667142

Набира участници Фаза 1

Autologous Tumour Vaccine Trial

Solid Tumor

Phase 1 trial to evaluate the feasibility of preparation, safety, tolerability and response to a personalised autologous tumour vaccine (ATV) formulated with Advax adjuvant when administered to patients with advanced solid cancers either as monotherapy or in combination with other standard of care agents

Начало: 10.02.2023 Край: 10.02.2028 Лечение

Australia Vaxine Pty Ltd NCT05807035

Набира участници Фаза 2

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Epilepsy Seizures, Epileptic

This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures

Начало: 07.02.2023 Край: 31.12.2027 Възраст: 18–70 г. Лечение

Australia, United States Supernus Pharmaceuticals, Inc. NCT05518578

Набира участници Фаза 4

Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study

Surgical Site Infection

This multicentre, adaptive, pragmatic, double-blind, three-arm, placebo-controlled, randomised, non-inferiority clinical trial will compare the incidence of surgical site infection and other healthcare associated infections, health economic and microbiological impact after intraoperative only (Arm A), to 24 hours (Arm B) and, to 48 hours (Arm C) of IV cefazolin and placebo postoperative surgical antimicrobial prophylaxis in patients undergoing cardiac surgery

Начало: 07.02.2023 Край: 01.06.2028 Възраст: от 18 г. Превенция

Australia, Canada, Malaysia +2 Monash University NCT05447559

1 … 170 171 172 173 174 … 222